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PROCESSING OF THE AMYLOID PRECURSOR PROTEIN 
GENERATES Aβ β PEPTIDES
The generation of Aβ peptides is due to enzymatic cleavage of the 
larger amyloid precursor protein (APP), which represents a type 
I membrane protein with a large N-terminal ectodomain and a 
short intracellular C-terminal domain. Alternative splicing of APP 
yields eight isoforms with lengths of 677–770 amino acid residues, 
of which APP695 is the primary transcript in neurons (Bayer et al., 
2001). APP can be processed by two different pathways: (i) non-
amyloidogenic processing: Cleavage by α-secretase within the Aβ 
domain releases a secreted form of APP (sAPPα), thereby preclud-
ing the generation of toxic Aβ peptides. Different members of the 
ADAM protein family (a disintegrin and metalloprotease) have 
been demonstrated to possess α-secretase activity (Buxbaum et al., 
1998; Lammich et al., 1999). (ii) Amyloidogenic processing: This 
APP processing pathway results in cleavage at the β-secretase site, 
liberating also a secreted form of APP (sAPPβ), and leading to the 
generation of a membrane-associated C-terminal fragment named 
C99. The β-site APP cleaving enzyme 1 (BACE) belongs to the fam-
ily of aspartyl proteases and has been identiﬁ  ed simultaneously by 
different research groups (Hussain et al., 1999; Sinha et al., 1999; 
Vassar et al., 1999; Yan et al., 1999). Subsequent cleavage of C99 by 
γ-secretase activity results in the generation of 40–42 residue Aβ 
peptides, as well as a short intracellular APP fragment named AICD. 
It has been shown that γ-secretase consists of a complex of differ-
ent proteins including presenilin-1 (PS1) or presenilin-2 (PS2), as 
well as nicastrin, anterior pharynx defective (APH-1) and presenilin 
enhancer 2 (PEN-2) (reviewed in Selkoe and Wolfe, 2007).
INTRODUCTION
Alzheimer’s disease (AD) represents the most frequent form of 
dementia and is characterized by two major neuropathological 
hallmarks: (i) extracellular plaques composed of the 40–42 resi-
dues Aβ peptide (Hardy and Allsop, 1991) and (ii) neuroﬁ  bril-
lary tangles, consisting of abnormal phosphorylated Tau protein 
(Braak and Braak, 1991). There is increasing evidence that, in 
addition to the well-known extracellular amyloid deposition in 
the parenchyma, Aβ peptides accumulate inside neurons (Gouras 
et al., 2000). It has been hypothesized that this initial accumulation 
is one of the earliest pathological events, thereby triggering the 
cascade leading to neurodegeneration (Wirths et al., 2004). Since 
their initial generation in the mid 1990s, transgenic mice have 
been proven to represent valuable model systems reﬂ  ecting various 
pathological subﬁ  elds of AD like plaque deposition, inﬂ  ammatory 
changes or behavioral abnormalities (reviewed in Games et al., 
2006; Duyckaerts et al., 2008). In the present review, we summa-
rize the current achievements of modeling early intraneuronal Aβ 
accumulation in transgenic mice with their resulting pathological 
consequences. Of special importance will be the critical discussion 
of this observation, because in all mouse models in which marked 
neuron loss has been so far reported, this was preceded by con-
siderable amounts of intraneuronal Aβ peptides. In the present 
short review, we will discuss the view that intraneuronal accumu-
lation of Aβ peptides leads to trafﬁ  c problems accompanied by 
early axonopathy, synaptic loss and neuron death. Extracellular 
plaque pathology, as we and others believe, has a weaker impact 
on neurodegeneration.
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Mutations in either APP or in the presenilin genes have been 
linked to familiar, early onset forms of AD. These cases repre-
sent only a minor portion (∼5%), whereas the vast majority of 
AD cases develop sporadically. Most of the reported APP muta-
tions are located near the secretase cleavage sites and lead to an 
overproduction of Aβ peptides. Some of these mutations (e.g. the 
Austrian mutation T714I), as well as a couple of PS1 mutations 
have a drastic effect on the Aβ42/Aβ40 ratio by strongly increasing 
Aβ42 production with concomitant suppression of Aβ40 secretion 
(Kumar-Singh et al., 2000; Wolfe, 2007).
SYNAPTIC PATHOLOGY IN ALZHEIMER’S DISEASE
The classical amyloid cascade hypothesis supports the idea that 
increased Aβ production and extracellular accumulation leads 
to progressive synaptic and neuronal injury ending up in wide-
spread neuronal dysfunction and dementia (Hardy and Selkoe, 
2002). However, despite of intense research efforts during the last 
20 years, the early molecular events leading to AD are still not clear. 
It has been shown that the loss of synaptic terminals correlates bet-
ter with cognitive decline than extracellular plaque load or loss of 
neurons, leading to the concept that losing synapses is one of the key 
events leading to cognitive dysfunction in AD (Terry et al., 1991). 
Neuropathological analyses conﬁ  rmed a loss of   synaptophysin-
immunoreactive synaptic terminals, e.g., in the outer molecular 
layer of the dentate gyrus in AD (Masliah et al., 1994), as well as a 
25% loss of synaptophysin-immunoreactivity already in mild AD 
cases in the frontal cortex (Masliah et al., 2001). Recently, it has 
been reported that mild AD patients had fewer synapses in the 
stratum radiatum of the CA1 subﬁ  eld (55%) than control patients 
and that patients suffering from mild cognitive impairment (MCI) 
had a mean synaptic value which was 18% lower than in the con-
trol group without cognitive impairment. These results further 
strengthen the hypothesis that synaptic loss is one of the earliest 
events in AD pathology and support the concept that MCI is a 
transitional stage between no cognitive impairment and mild AD 
(Scheff et al., 2007).
INTRANEURONAL Aβ β ACCUMULATION IN AD
The occurrence and relevance of intraneuronal Aβ accumulations 
in AD have been a matter of controversial scientiﬁ  c debate. First 
reports showing that Aβ is initially deposited in neurons before 
occurring in the extracellular space date back roughly 20 years 
(Masters et al., 1985; Grundke-Iqbal et al., 1989). More recently it 
has been shown that neurons in AD-vulnerable regions accumulate 
Aβ42 and it has been further suggested that this accumulation pre-
cedes neuroﬁ  brillary tangle formation and extracellular Aβ deposi-
tion (Gouras et al., 2000). Consecutively a variety of reports has 
been published demonstrating Aβ in neurons of AD (Mochizuki 
et al., 2000; D’Andrea et al., 2001, 2002; Fernandez-Vizarra et al., 
2004) and Down syndrome (DS) patients (Gyure et  al., 2001; 
Busciglio et al., 2002; Mori et al., 2002). On the contrary, a more 
recent study described intracellular Aβ immunoreactivity during 
the entire life span in control subjects and DS patients, leading 
to the suggestion that this represents rather a feature of normal 
neuronal metabolism than a pathological alteration. As the authors 
found the strongest intraneuronal Aβ in brain structures that are 
not highly vulnerable to AD-associated changes, they believe that 
intraneuronal Aβ immunoreactivity is not a predictor of brain 
  amyloidosis or neuroﬁ  brillary degeneration (Wegiel et al., 2007). 
Aoki and colleagues investigated whether Aβ levels are changed in 
CA1 pyramidal neurons of AD hippocampus, using laser capture 
microdissection to isolate neurons and enzyme-linked immuno-
sorbent assay for quantiﬁ  cation. The results showed increased Aβ42 
levels and an elevated Aβ42/Aβ40 ratio in neurons from sporadic as 
well as from familial AD cases, whereas Aβ40 levels remained unaf-
fected (Aoki et al., 2008). Recent reports have shown that modiﬁ  ca-
tions of the staining method have crucial inﬂ  uence on the detection 
of Aβ peptides in neurons. Whereas pretreatment of AD tissues 
using formic acid enhances the immunological detection of extra-
cellular plaques, it might have an opposing effect on intracellular 
Aβ peptides. Heat-induced antigen retrieval has been proposed to 
have the most signiﬁ  cant effect, whereas enzymatic treatment alone 
is not sufﬁ  cient (D’Andrea et al., 2003; Ohyagi et al., 2007). Fixation 
might also be an important point, as   intracellular Aβ detection 
in mice is well-documented (Wirths et al., 2001, 2002; Blanchard 
et al., 2003; Oddo et al., 2003; Casas et al., 2004; Lord et al., 2006; 
Oakley et al., 2006; Knobloch et al., 2007b), however, these tissues 
are usually ﬁ  xed by transcardial perfusion in a narrow time frame, 
whereas human material as a general rule is subjected to much 
longer post-mortem intervals.
ALTERNATE SOURCES OF INTRANEURONAL Aβ β
A second mechanism that contributes to intracellular Aβ accumula-
tion is uptake from the extracellular space, in addition to intraneu-
ronal Aβ production. It has been previously shown that cells that 
were treated with synthetic Aβ peptides, selectively accumulate 
Aβ42 and that this internalization could be prevented under condi-
tions that block endocytosis (Knauer et al., 1992). Uptake of Aβ1-42 
is enhanced by integrin antagonists and blocked by NMDA recep-
tor antagonists (Bi et al., 2002). Cultured hippocampal slices were 
exposed to Aβ1-42 for 6 days in the presence or absence of soluble 
Gly-Arg-Gly-Asp-Ser-Pro, a peptide antagonist of Arg-Gly-Asp 
(RGD)-binding integrins, or the disintegrin  echistatin. Aβ uptake, 
as assessed with immunocytochemistry, occurred in 42% of the 
slices incubated with Aβ peptide alone but in more than 80% 
of the slices co-treated with integrin antagonists. The selective 
NMDA receptor antagonist D-(-)-2-amino-5-  phosphonovalerate 
completely blocked internalization of Aβ (Bi et al., 2002). On the 
subcellular level, internalized Aβ42 peptides seem to accumulate 
especially in the endosomal/lysosomal system which leads to lys-
osomal permeability and membrane damage (Yang et al., 1998; 
Ditaranto et al., 2001). One possible internalization mechanism 
might be cell-surface receptor-mediated uptake via the α7 nicotinic 
acetylcholine receptor (Nagele et al., 2002), but also passive diffu-
sion of extracellular Aβ through the plasma membrane has been 
suggested (Li et al., 2007).
A selective Aβ42 uptake was revealed in the CA1 subﬁ  eld of rat 
organotypic slice cultures, whereas other hippocampal regions like 
CA3 and dentate gyrus remained almost unaffected (Bahr et al., 
1998). Primary neurons from APP transgenic Tg2576 mice accu-
mulate Aβ peptides and have been shown to undergo selective 
reductions in synaptic levels of PSD-95 and the glutamate recep-
tor subunit GluR1 compared to the wild-type situation (Almeida 
et al., 2005). As Aβ has been implicated in the depression of AMPA Frontiers in Aging Neuroscience  www.frontiersin.org  March 2010  | Volume 2  |  Article 8  |  3
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receptor currents, thereby regulating synaptic activity (Kamenetz 
et al., 2003), reduced levels of GluR1 provide a molecular basis 
for Aβ-induced AMPA current alterations (Almeida et al., 2005). 
Wang et al. reported that Aβ1-42 inhibits alpha7nAChR-dependent 
calcium activation and acetylcholine release, two processes critically 
involved in memory and cognitive functions (Wang et al., 2000). 
Internalization of Aβ1-42 may be facilitated by the high-afﬁ  nity 
binding to the alpha7 receptor on neuronal cell surfaces, followed 
by endocytosis of the resulting complex (Nagele et  al., 2002). 
Dziewczapolski et al. have shown that, despite the presence of high 
amounts of APP and amyloid deposits, deleting the alpha7nAChR 
subunit in PDAPP mice leads to a protection from the dysfunction 
in synaptic integrity (pathology and plasticity) and learning and 
memory behavior. APP/alpha7nAChR KO mice express APP and 
Aβ at levels similar to APP mice, however they were able to solve a 
cognitive challenge such as the Morris water maze test signiﬁ  cantly 
better than APP single transgenic mice, with performances com-
parable to control groups. Moreover, deleting the alpha7nAChR 
subunit protected the brain from loss of the synaptic markers 
synaptophysin and MAP2, reduced the gliosis, and preserved the 
capacity to elicit long-term potentiation (LTP) which is deﬁ  cient 
in the single transgenic APP mice used. These results are consistent 
with the hypothesis that the alpha7nAChR plays a role in AD and 
suggest that interrupting alpha7nAChR function could be beneﬁ  -
cial in the treatment of AD (Dziewczapolski et al., 2009).
MITOCHONDRIAL DYSFUNCTION AND INTRANEURONAL Aβ β
Reviewed in detail, there is increasing evidence that oxidative dam-
age, induced by Aβ, is associated with mitochondrial dysfunction 
early in AD development (Reddy and Beal, 2008). Aβ binds to alco-
hol dehydrogenase (ABAD) demonstrating a direct molecular link 
from Aβ to mitochondrial toxicity in AD patients and transgenic 
mice. The crystal structure of Aβ-bound ABAD showed substan-
tial deformation of the active site inhibiting nicotinamide adenine 
dinucleotide (NAD) binding (Lustbader et al., 2004). Of interest, 
intracellular Aβ is present in mitochondria in brains from APP 
transgenic mice and AD patients. It has been shown that Aβ pro-
gressively accumulated in mitochondria and was associated with 
diminished enzymatic activity of respiratory chain complexes 
(III and IV) and a reduction in the rate of oxygen consumption 
(Caspersen et al., 2005). In addition, cytochrome c oxidase activity 
was found to be decreased in Tg2576 mice, suggesting that mutant 
APP and/or soluble Aβ impair mitochondrial metabolism in AD 
development and progression (Manczak et al., 2006).
Treatment of cultured hippocampal neurons with Aβ resulted 
in rapid and severe impairment of mitochondrial transport with-
out inducing apparent cell death and signiﬁ  cant morphological 
changes, whereas stimulation of protein kinase A (PKA) by for-
skolin, cAMP analogs or neuropeptides effectively alleviated the 
impairment. In addition, Aβ inhibited mitochondrial transport by 
acting through glycogen synthase kinase 3β (GSK3β) (Rui et al., 
2006). Mitochondrial damage such as reduced mitochondrial mem-
brane potential and ATP levels have been detected in the brains 
from APP and APP/PS1 transgenic mice before the onset of plaques 
arguing for a role of intracellular and/or soluble Aβ on mitochon-
drial dysfunction (Eckert et al., 2008). Results from rat mitochon-
dria demonstrated that Aβ is transported into mitochondria via the 
translocase of the outer membrane (TOM) machinery. Subcellular 
fractionation studies following the import experiments revealed 
Aβ association with the inner membrane fraction, and immuno-
electron microscopy after import showed localization of Aβ to 
mitochondrial cristae. In addition, it could be demonstrated that 
extracellularly applied Aβ was taken up by human neuroblastoma 
cells which then colocalized with mitochondrial markers (Hansson 
Petersen et al., 2008). It has also been reported that the receptor 
for advanced glycation end products (RAGE) contributes to trans-
port of Aβ from the cell surface to the intracellular space. Mouse 
cortical neurons were treated with extracellular human Aβ show-
ing detectable Aβ intracellularly in the cytosol and mitochondria 
by confocal and immunogold electron microscopy. Intraneuronal 
co-localization of Aβ and RAGE was also observed in the 
  hippocampus of APP transgenic mice (Takuma et al., 2009). Very 
recently, a drosophila model was described in which overexpression 
of Aβ, resulting in Aβ accumulation in the soma and axons of neu-
rons, leads to a variety of mitochondrial abnormalities including 
depletion of presynaptic and axonal mitochondria, a decrease in 
axonal transport of mitochondria, as well as changes in mitochon-
drial size and number (Zhao et al., 2010).
Aβ β OLIGOMERS AND SYNAPTIC DYSFUNCTION
Aβ protein assembly and oligomer formation has been reviewed 
extensively in the past (for example, Klein et al., 2001; Klein, 2002; 
Roychaudhuri et al., 2009) and is therefore not a focus of the 
present review. The formation of Aβ oligomers has been repeat-
edly reported to contribute signiﬁ  cantly to the pathophysiological 
alterations underlying AD and it has been shown that soluble oli-
gomeric Aβ42 and not plaque-associated Aβ correlates best with 
cognitive dysfunction (McLean et al., 1999; Naslund et al., 2000). 
Oligomers are formed preferentially intracellularly within neuronal 
processes and synapses rather than within the extracellular space 
(Walsh et al., 2000; Takahashi et al., 2004) and have been demon-
strated to cause synaptic alterations (Lacor et al., 2004, 2007). These 
oligomers have been previously demonstrated to inhibit hippocam-
pal LTP and disrupt synaptic plasticity (Lambert et al., 1998; Walsh 
et al., 2002) and have been shown to originate from intraneuronal 
rather than extracellular dimerization (Walsh et al., 2000). By the 
use of antibodies raised against synthetic Aβ oligomer assemblies, 
these oligomers or Aβ-derived diffusible ligands (ADDLs) have 
detected in up to 70-fold higher concentrations in AD compared 
to control brains (Gong et al., 2003). However, as these oligomers 
normally occur both inside neurons as well as in a secreted form, 
it is difﬁ  cult to attribute the toxic actions to one of the different 
entities. In addition, it has been shown that Aβ-derived oligomers 
speciﬁ  cally bind to pyramidal neurons, promoting a rapid decrease 
in the membrane expression levels of memory-related receptors 
like NMDA or EphB2 (Lacor et al., 2007). In hippocampal neu-
ron cultures, ADDLs stimulated the excessive formation of reac-
tive oxygen species (ROS) through a mechanism requiring NMDA 
receptor activation. Interestingly, the memory-preserving drug 
memantine, which represents a NMDA receptor antagonist, com-
pletely protected against these toxic effects, indicating that ADDLs 
bind to NMDA receptors and trigger neuronal damage through 
 receptor-dependent calcium inﬂ  ux (De Felice et al., 2007). In addi-
tion, concentrations of soluble Aβ clearly distinguished healthy Frontiers in Aging Neuroscience  www.frontiersin.org  March 2010  | Volume 2  |  Article 8  |  4
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 controls from AD patients and represent a strong inverse correlate 
of synapse loss (Lue et al., 1999; McLean et al., 1999). In addi-
tion to ADDLs, globular Aβ species called globulomers have been 
found to be toxic (Barghorn et al., 2005) and suppressed spontane-
ous synaptic activity by inhibition of P/Q-type calcium currents 
(Nimmrich et al., 2008).
TRANSGENIC AD MOUSE MODELS WITH INTRANEURONAL 
Aβ β ACCUMULATION AND SYNAPTIC PATHOLOGY
The data in AD mouse models regarding intraneuronal Aβ are 
much more consistent and an increasing consensus can be observed 
during the past years. Intraneuronal Aβ was ﬁ  rst reported in familial 
PS1 transgenic mice that also showed neurodegeneration without 
the formation of plaque pathology (Chui et al., 1999). During the 
last years, intraneuronal accumulation has been reported in sev-
eral mouse models including APPSDLPS1M146L (Wirths et al., 2001), 
APPSLPS1M146L (Wirths et al., 2002), Tg2576 (Takahashi et al., 2002), 
3xTg-AD (Oddo et al., 2003), 5xFAD (Oakley et al., 2006), APPArc 
(Lord et al., 2006; Knobloch et al., 2007b), APPT714I mice (Van 
Broeck et al., 2008), in APPSLPS1KIM233T, L235P mice (Casas et al., 
2004) in which it was recently shown to correlate with neuron loss 
(Christensen et al., 2008a,b; Breyhan et al., 2009), as well as in TBA2 
mice expressing pyroglutamate modiﬁ  ed Aβ3-42 (Wirths et al., 
2009). These models differ in a variety of parameters including the 
expressed APP isoform, the APP mutations included, the expression 
level of APP, the promoter construct used to drive expression of the 
transgene, as well as in the fact whether they are single or multi-
transgenic (co-expression of Presenilin-1 or Tau) (see Table 1).
Early intraneuronal Aβ accumulation preceding extracellular 
amyloid plaque pathology has been detected in a model express-
ing APP751 with the Swedish and London mutations (APP751SL), 
in combination with transgenic mutant human PS1 with the 
M146L mutation expressed under the control of the HMG-CoA-
reductase promoter. Strong Aβ staining was identiﬁ  ed in soma-
todendritic compartments of neurons in subiculum, CA1 region 
of the   hippocampus, as well as in cortical areas already in young 
mice (Wirths et  al., 2002; Blanchard et  al., 2003). It has been 
shown that with incremental extracellular pathology an attenu-
ated intraneuronal Aβ immunoreactivity was noted (Wirths et al., 
2002; Langui et al., 2004). This ﬁ  nding corroborates an observation 
in DS patients, where consistently strong cellular Aβ staining was 
reported in young patients, with a progressive decline paralleling 
deposition and maturation of extracellular amyloid plaques (Mori 
et al., 2002). A detailed stereological analysis revealed that both 
the single transgenic APP751SL mice and PS1M146L mice showed 
an age-related loss of synaptophysin-immunoreactive presynap-
tic boutons (SIPBs) within the stratum radiatum. Importantly, 
APP751SL/PS1M146L mice displayed the most severe age-related SIPB 
loss within stratum moleculare, stratum lacunosum and stratum 
radiatum, even in regions free of extracellular Aβ deposits (Rutten 
et al., 2005).
Analysis of the subcellular localization of Aβ peptides by means 
of double-ﬂ  uorescence experiments in these mice revealed that 
intracellular Aβ colocalized with lysosomal markers and less fre-
quently with markers of the trans-Golgi network (TGN). Using 
electron microscopy, Aβ has been detected in the lumen of mul-
tivesicular bodies (MVBs) (Langui et al., 2004), corroborating an 
earlier report in Tg2576 mice showing that Aβ42 is localized pre-
dominantly to MVBs within pre- and postsynaptic compartments 
(Takahashi et al., 2002). In Tg2576 mice an altered synaptic mor-
phology has been recognized which preceded extracellular amyloid 
deposition (Takahashi et al., 2002) and it has been shown in a subse-
quent report that Aβ42 aggregates into oligomers within endosomal 
vesicles, as well as in neuronal processes (Takahashi et al., 2004). 
This is particularly interesting as it has been hypothesized that Aβ 
oligomers have a signiﬁ  cant impact on the pathological alterations 
underlying memory deﬁ  cits in AD patients, as they have been dem-
onstrated to disrupt synaptic plasticity and to inhibit hippocampal 
LTP (Lambert et al., 1998; Walsh et al., 2002). Using stereology at 
the light and electron microscopy level, synapse density was assessed 
in Tg2576 mice in hippocampus and entorhinal cortex. No overall 
decrease in the density of synaptophysin-positive boutons could 
Table 1 | Overview of transgenic AD mouse models in which intraneuronal Aβ accumulation has been reported. In addition, information on extracellular 
plaque onset, neuron loss and synaptic pathology are given (n.a., not analyzed).
Transgenic   Mutation APP  Mutation PS1  Promoter  Plaque onset  Neuron loss  Synaptic   Reference
mouse model            alterations
APP695SDLx/  Swedish, Dutch,   M146L  PDGF (APP),   8m  No  n.a.  Wirths et al. (2001)
PS1M146L  London   HMG-CoA (PS1)
APP751SLx/  Swedish, London  M146L  Thy1 (APP),   3m  Yes (17m)  Yes  Rutten et al. (2005), 
PS1M146L     HMG-CoA (PS1)        Wirths et al. (2002)
Tg2576  Swedish  –  Hamster prion   12m  No  Yes  Dong et al. (2007), 
     protein        Takahashi et al. (2002)
3xTg-AD  Swedish  M146V  Thy1 (APP, Tau),   6m  n.a.  Yes  Billings et al. (2005), 
     PS1 knock-in        Oddo et al. (2003)
APP751SL/  Swedish, London  M233T, L235P  Thy1 (APP),   2m  Yes (6m)  Yes  Bayer and Wirths (2008), 
PS1KI     PS1 knock-in        Breyhan et al. (2009)
arcAβ  Swedish, Arctic  –  Mouse prion  7m  n.a.  Yes  Knobloch et al. (2007a)
     protein
5XFAD  Swedish, Florida,   M146L, L286V  Thy1 (APP, PS1)  2m  Yes  Yes  Oakley et al. (2006)
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be found on the light microscopy level, however, using electron 
microscopy, an overall decreases in synapse density in the outer 
molecular layer of the dentate gyrus at both 6–9 and 15–18 months 
of age, and in Layers II and III of the entorhinal cortex at 15–18 
months of age was detected (Dong et al., 2007).
A further interesting model expresses APP with the Swedish 
and London mutations on a homozygous mutant PS1 knock-in 
background (APP/PS1KI). These animals show early extracellular 
amyloid deposition at the age of 2 months, which is preceded by 
strong intraneuronal Aβ accumulation in hippocampus, cortex and 
motor neurons of the spinal cord (Figures 1E,F). Staining with the 
β-sheet binding dye Thioﬂ  avin-S indicated that the intraneuronal 
Aβ is aggregated and is present in the form of β-pleated sheets. 
Further pathological features include severe axonal degeneration, as 
well as motor and cognitive deﬁ  cits starting at the age of 6 months 
(Casas et al., 2004; Wirths et al., 2007, 2008; Bayer and Wirths, 2008). 
At this time point also synaptic alterations became evident. The 
levels of the postsynaptic marker protein PSD-95 were signiﬁ  cantly 
decreased in whole brain lysates. In addition, analysis of synapto-
some-enriched fractions revealed a signiﬁ  cant decrease in the lev-
els of the presynaptic markers SNAP25 and clathrin-light chain, 
as well as of the postsynaptic marker PSD-95. Recordings of ﬁ  eld 
FIGURE 1 | Intraneuronal Aβ accumulation and impaired LTP in APP/PS1KI 
mice. Schematic drawing of the hippocampus (A). At 6 months of age deﬁ  cits in 
synaptic transmission in the form of altered LTP are detected in APP/PS1KI mice 
(B–D). Intraneuronal accumulation of Aβ peptides occurs already at 2 months of 
age in the CA1 region of the hippocampus (E) and precedes neuron loss which 
becomes evident at 6 months of age (F,G).Frontiers in Aging Neuroscience  www.frontiersin.org  March 2010  | Volume 2  |  Article 8  |  6
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  excitatory   postsynaptic potentials (fEPSPs) disclosed a signiﬁ  cant 
reduction of fEPSPs in 6-month-old APP/PS1KI compared to PS1KI 
or wild-type mice (Figures 1A–D). Short-term synaptic plasticity 
was also affected, as 6-month-old APP/PS1KI mice disclosed unal-
tered paired pulse facilitation (PPF) ratios before and after LTP, in 
contrast to PS1KI and WT mice, which showed the expected lower 
PPF ratios after LTP induction (Breyhan et al., 2009).
Mice expressing human APP with the Arctic mutation (E693G) 
have been recently developed (Lord et al., 2006; Knobloch et al., 
2007b). This mutation is particularly interesting as it has been dem-
onstrated that protoﬁ  brils are produced at a much higher rate and in 
larger quantities than wild-type Aβ (Nilsberth et al., 2001). The avail-
able mouse models express APP with both the Swedish and the Artic 
mutation. A transgenic line named tg-APPArcSwe mice has been created 
under the control of the murine Thy1 promoter. Strong intraneu-
ronal Aβ immunostaining was observed at 2 months of age, which 
preceded plaque formation occurring at 5–6 months of age (Lord 
et al., 2006). Another mouse line named ArcAβ uses the murine prion 
protein promoter to express APP695 with the Swedish and Arctic 
mutations. These mice show intracellular Aβ staining already at 3 
months of age, with increasing amounts during aging. Interestingly, 
these mice develop age-dependent cognitive impairments, as shown 
by deﬁ  cits in behavior tasks like the Y-maze or a two-way active 
avoidance paradigm (Knobloch et al., 2007b). Hippocampal LTP 
measurements disclosed a severe LTP impairment in young mice 
already at 3.5 and 7.5 months of age, which was obviously not due 
to developmental defects, as 1-month-old mice showed normal LTP 
and basal synaptic transmission. The mutations used in this model 
render Aβ to be more prone to oligomer formation, which was held 
responsible for this effect as it could be reversed by a single dose of 
an antibody directed against the Aβ sequence administered to the 
animals 48 h before LTP induction (Knobloch et al., 2007a).
Recently a triple transgenic mouse model has been developed 
expressing both APP and Tau on a mutant PS1 knock-in background 
(3xTg-AD mice) (Oddo et al., 2003). Intracellular Aβ is apparent 
between 3 and 4 months in these mice and precedes the deposition 
of extracellular Aβ peptides starting around the age of 6 months. 
At this time point synaptic plasticity was already strongly compro-
mised in these mice, as shown by impaired LTP (Oddo et al., 2003). 
Intracellular Aβ accumulation is functionally linked to cognitive 
impairment in these mice, as they develop deﬁ  cits in long-term 
retention at the age of 4 months, a time point prior to plaque depo-
sition where only intracellular Aβ is present (Billings et al., 2005). 
Morphological alterations of hippocampal synapses have been char-
acterized in 13-month-old 3xTg-AD mice and age-matched PS1KI 
control mice. The numeric density of synapses, the average synaptic 
contact area, as well as the synaptic surface density were not altered, 
however, 3xTg-AD mice disclosed a signiﬁ  cant decrease in the frac-
tion of perforated synapses, which is believed to represent a reliable 
indirect index of synaptic plasticity (Bertoni-Freddari et al., 2008).
5XFAD mice express human APP with the Swedish, Florida 
(I716V) and London mutations, together with mutant PS1 (M146L, 
L286V) under the control of the murine Thy1 promoter (Oakley 
et al., 2006). The earliest intracellular Aβ accumulation could be 
detected at 1.5 months of age, immediately preceding extracellular 
plaque deposition occurring at the age of 2 months. The intraneu-
ronal Aβ is in an aggregated state, as shown by Thioﬂ  avin-S staining 
and memory impairment, as shown by a reduced Y-maze perform-
ance and deﬁ  cits in trace fear conditioning, compared to wild-
type control animals, became evident already at the age of 4–5 and 
5–6 months respectively (Oakley et al., 2006; Ohno et al., 2007). 
Synaptic pathology in this model was demonstrated by reduced 
synaptophysin, syntaxin and PSD-95 levels in whole brain lysates. 
Synaptophysin levels start to decline already at 4 months of age 
and from 9 months on signiﬁ  cantly reduced levels of syntaxin and 
PSD-95 were described (Oakley et al., 2006).
Early pathological changes like impaired synaptic transmission 
have been also reported in other transgenic AD mouse models, 
where intraneuronal Aβ accumulation has not been reported. In 
APP transgenic mice harboring the Swedish and Indiana mutations 
under the control of the PGDFβ-Promoter, deﬁ  cits in synaptic trans-
mission became evident prior to extracellular plaque formation. 
Without showing direct experimental evidence, the authors specu-
lated that this might be due to neurotoxic effects possibly induced 
by intraneuronal Aβ accumulation or diffusible Aβ oligomers (Hsia 
et al., 1999). Another transgenic model, expressing APP with the 
London mutation, showed early behavioral changes, differential 
glutamate responses, as well as deﬁ  cits in LTP, all occurring before 
extracellular plaque formation (Moechars et al., 1999). Finally, single 
APP (Swedish) and double APP (Swedish) and PS1 (M146L) trans-
genic mice were reported to show a reduced spontaneous alterna-
tion performance in the Y-maze task, before substantial extracellular 
plaque pathology became evident. The authors suggested that at 
least some aspects of the behavioral phenotype might be due to 
pathological alterations preceding plaque formation (Holcomb 
et al., 1999). In summary, we think that it would be worthwhile 
to examine the models with phenotypical changes prior to plaque 
formation on the occurrence of intraneuronal Aβ aggregates.
AD MOUSE MODELS WITH NEURON LOSS AND 
INTRANEURONAL Aβ β ACCUMULATION
Despite of a plethora of transgenic AD mouse models express-
ing various APP isoforms and mutations, efforts modeling sig-
niﬁ  cant neuronal loss were, until recently, not successful (Irizarry 
et al., 1997a,b). First evidence for signiﬁ  cant hippocampal neuron 
loss (−14%), was reported in the APP23 mouse model, where the 
number of CA1 neurons was inversely correlated with CA1 plaque 
load (Calhoun et al., 1998).
Using unbiased stereologic methods, a loss of CA1-3 neurons 
in a magnitude of ∼30% was detected in 17-month-old APP/PS1 
transgenic mice, compared to age-matched PS1 control animals. 
Interestingly, the plaque load was approximately 10% smaller than 
the level of hippocampal pyramidal cell loss in these mice, indicat-
ing a loss of neurons at sites of Aβ aggregation but additionally also 
distant from extracellular Aβ deposits (Schmitz et al., 2004).
Another model showing massive hippocampal neuron loss is the 
abovementioned APP/PS1KI mouse model (Casas et al., 2004). At 
the age of 10 months an extensive neuron loss (>50%) in the hip-
pocampus was reported, that correlated with the accumulation of 
intraneuronal Aβ and Thioﬂ  avin-S positive intracellular material and 
was already detectable at the age of 6 months (Casas et al., 2004). At 
this time point, a loss of 33% of CA1 pyramidal neurons compared 
to PS1KI littermates could be demonstrated (Figure 1G), together 
with decreased CA1 volume (−30%) and an atrophy of the entire Frontiers in Aging Neuroscience  www.frontiersin.org  March 2010  | Volume 2  |  Article 8  |  7
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hippocampus of 18% (Breyhan et al., 2009). A detailed stereological 
analysis of the frontal cortex revealed an early loss of cortical neurons 
starting at the age of 6 months which correlated with the transient 
intraneuronal Aβ accumulation in contrast to extracellular plaque 
pathology (Christensen et al., 2008b). A related observation was 
made in distinct cholinergic brain stem nuclei (Mo5, 7N) in these 
mice, where neuronal loss at 6 or 12 months of age correlated with the 
presence of intraneuronal Aβ peptides (Christensen et al., 2008a).
The 5XFAD mice underscore the potential inﬂ  uence of intraneu-
ronal Aβ accumulation on the loss of neurons. Cresyl violet staining 
revealed a reduced number of cortical layer 5 neurons, a region 
with robust intracellular Aβ immunoreactivity. The same holds 
true for the subiculum where neurons where pale or entirely miss-
ing (Oakley et al., 2006). However, unbiased stereological neuron 
quantiﬁ  cations are needed to disclose the onset and severity of 
neuron loss in this model.
Recently, a new mouse model expressing only N-truncated 
AβpE3-42 in neurons was generated and it was demonstrated for the 
ﬁ  rst time that this peptide is neurotoxic in vivo inducing neuron loss 
and an associated neurological phenotype (Wirths et al., 2009).
CONCLUSION
In summary, there is accumulating evidence demonstrating that 
intraneuronal Aβx-42 triggers early synaptic deﬁ  cits and neuron 
loss. Extracellular Aβ deposition has been challenged in the past to 
be a correlate for the striking region speciﬁ  c neuron loss, like the 
layer two pyramidal neurons in the entorhinal cortex and the CA1 
neurons in the hippocampus (reviewed in Morrison and Hof, 1997). 
Among other interesting mouse models for AD, APP/PS1KI mice 
show early intraneuronal aggregation of full-length and N- terminal 
modiﬁ  ed Aβx-42 peptides. Evidence has been demonstrated that 
these peptides are aggregated as shown by the OC antibody and 
Thioﬂ  avin-S staining. The time point of loss of LTP and disrupted 
PPF correlates with CA1 neuron loss, hippocampus atrophy and 
hippocampus-dependent deﬁ  cits in learning and memory behavior 
in this model. This was accompanied by reduced levels of pre- 
and postsynaptic markers (Breyhan et al., 2009). Aβ42 comprises 
85% of the total Aβ in this model, consisting of full-length and 
heterogeneous N-terminal modiﬁ  ed Aβ variants. The APP/PS1KI 
model is so far the model with the most aggressive pathology (Casas 
et al., 2004). Together with the data obtained from other transgenic 
mouse models, these data demonstrate that both synaptic deﬁ  cits 
and neuron loss are a consequence of intraneuronal accumulation 
of Aβ peptides.
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